{
    "address": "Karlstads universitet Biomedicin, Universitetsgatan 2",
    "city": "Karlstad",
    "country": "SE",
    "currency": "SEK",
    "cusip": "W3993L101",
    "description": "Hemcheck Sweden AB is a medical technology company, which engages in the production and development of concept for point-of-care detection of hemolysis. The company is headquartered in Karlstad, Varmland. The company went IPO on 2017-03-15. The Company\u2019s product development focuses on issue of hemolyzed blood samples. The offer implies product HELGE that is a simple, single use test that detects hemolysis in blood samples at the point of care. HELGE is used directly on the blood sample without affecting or altering it. The company consists of a needle that penetrates the test tube cap. A small amount of whole blood enters the test and plasma is separated. This plasma gets transferred to a detection field and display window changes color when hemolysis is detected. HELGE has a needle shield for protection of the operator. The Company\u2019s customers primarily consist of hospitals where blood samples are mainly taken.",
    "employeeTotal": "",
    "exchange": "NASDAQ OMX NORDIC",
    "finnhubIndustry": "Health Care",
    "ggroup": "Health Care Equipment & Services",
    "gind": "Health Care Equipment & Supplies",
    "gsector": "Health Care",
    "gsubind": "Health Care Supplies",
    "ipo": "2017-03-15",
    "isin": "SE0009320278",
    "logo": "",
    "marketCapitalization": 62.87963,
    "naics": "Pharmaceutical and Medicine Manufacturing",
    "naicsNationalIndustry": "In-Vitro Diagnostic Substance Manufacturing",
    "naicsSector": "Manufacturing",
    "naicsSubsector": "Chemical Manufacturing",
    "name": "Hemcheck Sweden AB",
    "phone": "",
    "sedol": "BYXYLS1",
    "shareOutstanding": 24.31823,
    "state": "VARMLAND",
    "ticker": "HEMC.ST",
    "weburl": "https://hemcheck.com/"
}